S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)
S&P 500   4,594.63 (+0.59%)
DOW   36,245.50 (+0.82%)
QQQ   389.94 (+0.29%)
AAPL   191.24 (+0.68%)
MSFT   374.51 (-1.16%)
META   324.82 (-0.71%)
GOOGL   131.86 (-0.51%)
AMZN   147.03 (+0.64%)
TSLA   238.83 (-0.52%)
NVDA   467.65 (-0.01%)
NIO   7.16 (-1.51%)
BABA   73.98 (-1.20%)
AMD   121.39 (+0.19%)
T   16.77 (+1.21%)
F   10.58 (+3.02%)
MU   75.93 (-0.25%)
CGC   0.62 (+10.75%)
GE   122.50 (+0.57%)
DIS   92.55 (-0.15%)
AMC   6.87 (+3.16%)
PFE   28.91 (-5.12%)
PYPL   59.65 (+3.54%)
XOM   102.99 (+0.24%)

ImmunoPrecise Antibodies Stock Price, News & Analysis (NASDAQ:IPA)

$1.70
+0.13 (+8.28%)
(As of 12/1/2023 ET)
Compare
Today's Range
$1.51
$1.75
50-Day Range
$1.14
$2.30
52-Week Range
$1.14
$5.90
Volume
47,464 shs
Average Volume
60,405 shs
Market Capitalization
$42.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

ImmunoPrecise Antibodies MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
370.6% Upside
$8.00 Price Target
Short Interest
Healthy
0.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.24mentions of ImmunoPrecise Antibodies in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.35) to ($0.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

284th out of 949 stocks

Pharmaceutical Preparations Industry

117th out of 442 stocks


IPA stock logo

About ImmunoPrecise Antibodies Stock (NASDAQ:IPA)

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

IPA Stock Price History

IPA Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
ImmunoPrecise Antibodies Announces CFO Transition
ImmunoPrecise Antibodies (IPA) Receives a Buy from H.C. Wainwright
IPA Announces Board Refreshment
IPA Responds to 13D Filing
See More Headlines
Receive IPA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/14/2023
Today
12/01/2023
Next Earnings (Estimated)
12/21/2023
Fiscal Year End
4/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IPA
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$9.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+370.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-19,980,000.00
Pretax Margin
-100.04%

Debt

Sales & Book Value

Annual Sales
$15.61 million
Book Value
$1.74 per share

Miscellaneous

Free Float
23,339,000
Market Cap
$42.59 million
Optionable
Not Optionable
Beta
0.32
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Ilse Roodink
    Chief Scientific Officer & Interim General Manager of IPA Europe, Oss
  • Dr. Barry Neil Duplantis
    Vice President of Client Relations
  • Ms. Kristin Taylor CPA
    M.B.A., Chief Financial Officer
  • Mr. David E. Orton
    Chief Operating Officer
  • Dr. Roland Romijn
    Head of General Operations of the Utrecht site of IPA (Europe)














IPA Stock Analysis - Frequently Asked Questions

Should I buy or sell ImmunoPrecise Antibodies stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoPrecise Antibodies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IPA shares.
View IPA analyst ratings
or view top-rated stocks.

What is ImmunoPrecise Antibodies' stock price target for 2024?

2 Wall Street analysts have issued 1 year price targets for ImmunoPrecise Antibodies' shares. Their IPA share price targets range from $7.00 to $9.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 370.6% from the stock's current price.
View analysts price targets for IPA
or view top-rated stocks among Wall Street analysts.

How have IPA shares performed in 2023?

ImmunoPrecise Antibodies' stock was trading at $5.21 at the beginning of the year. Since then, IPA stock has decreased by 67.4% and is now trading at $1.70.
View the best growth stocks for 2023 here
.

Are investors shorting ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 29,000 shares, a decline of 38.3% from the October 31st total of 47,000 shares. Based on an average trading volume of 65,100 shares, the short-interest ratio is presently 0.4 days. Currently, 0.1% of the shares of the company are sold short.
View ImmunoPrecise Antibodies' Short Interest
.

When is ImmunoPrecise Antibodies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, December 21st 2023.
View our IPA earnings forecast
.

How were ImmunoPrecise Antibodies' earnings last quarter?

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) released its quarterly earnings data on Thursday, September, 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.06. The company earned $4.26 million during the quarter, compared to analysts' expectations of $3.98 million. ImmunoPrecise Antibodies had a negative net margin of 95.81% and a negative trailing twelve-month return on equity of 35.22%.

Who are ImmunoPrecise Antibodies' major shareholders?

ImmunoPrecise Antibodies' stock is owned by many different retail and institutional investors. Top institutional investors include Ingalls & Snyder LLC (4.10%), Rathbones Group PLC (0.06%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of ImmunoPrecise Antibodies?

Shares of IPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:IPA) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -